company background image
EMBC logo

Embecta NasdaqGS:EMBC Stock Report

Last Price

US$10.04

Market Cap

US$558.7m

7D

1.3%

1Y

-20.1%

Updated

16 Jun, 2025

Data

Company Financials +

Embecta Corp.

NasdaqGS:EMBC Stock Report

Market Cap: US$558.7m

Embecta (EMBC) Stock Overview

A medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes in the United States and internationally. More details

EMBC fundamental analysis
Snowflake Score
Valuation5/6
Future Growth3/6
Past Performance0/6
Financial Health0/6
Dividends4/6

Rewards

Trading at 60.5% below our estimate of its fair value

Earnings are forecast to grow 30.21% per year

Trading at good value compared to peers and industry

Risk Analysis

Interest payments are not well covered by earnings

Negative shareholders equity

Large one-off items impacting financial results


EMBC Community Fair Values

Create Narrative

See what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.

INBS logo
Intelligent Bio Solutions
JO
Jolt_Communications
Community Contributor

The Future of Drug Testing? Fingerprint Tech Shows Serious Promise

Key Takeaways Intelligent Bio Solutions has a new way to test for drugs using fingerprints: it’s quick, portable, and doesn’t require pee cups or saliva swabs. With commercial traction in 24 countries and over 450 active accounts, INBS is now targeting the U.S. market, where over 55 million drug tests are performed annually.
View narrative
US$2.98
FV
36.2% undervalued intrinsic discount
59.20%
Revenue growth p.a.
7users have liked this narrative
0users have commented on this narrative
36users have followed this narrative
12 days ago author updated this narrative
EMBC logo
Embecta
AN
AnalystConsensusTarget
Consensus Narrative from 4 Analysts

Debt Reduction And Partnerships Will Strengthen Future Market Position

Key Takeaways Expanding product portfolio and distribution agreements could drive revenue growth through enhanced revenue streams and market diversification. Cost-saving restructuring, debt reduction, and brand transition may enhance financial flexibility, net margins, and global market position.
View narrative
US$20.25
FV
50.4% undervalued intrinsic discount
-0.033%
Revenue growth p.a.
1users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
6 days ago author updated this narrative
EMBC logo
Embecta
AN
AnalystHighTarget
Consensus Narrative from 4 Analysts

Aging And Digital Health Trends Will Open Diabetes Care Opportunities

Key Takeaways Strategic restructuring, innovation investment, and tailored partnerships are expected to accelerate margin expansion, debt reduction, and exposure to high-growth diabetes and GLP-1 markets. Global presence, operational readiness, and strong clinical reputation position the company for robust, sustained growth and improved competitive differentiation.
View narrative
US$25.00
FV
59.8% undervalued intrinsic discount
0.56%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
6 days ago author updated this narrative
View Embecta Community

Embecta Corp. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Embecta
Historical stock prices
Current Share PriceUS$10.04
52 Week HighUS$21.48
52 Week LowUS$9.49
Beta1.08
1 Month Change-16.47%
3 Month Change-25.52%
1 Year Change-20.13%
3 Year Change-64.47%
5 Year Changen/a
Change since IPOn/a

Recent News & Updates

Embecta (NASDAQ:EMBC) Has Announced A Dividend Of $0.15

May 22
Embecta (NASDAQ:EMBC) Has Announced A Dividend Of $0.15

Recent updates

Embecta (NASDAQ:EMBC) Has Announced A Dividend Of $0.15

May 22
Embecta (NASDAQ:EMBC) Has Announced A Dividend Of $0.15

What Is Embecta Corp.'s (NASDAQ:EMBC) Share Price Doing?

May 09
What Is Embecta Corp.'s (NASDAQ:EMBC) Share Price Doing?

Embecta Corp.'s (NASDAQ:EMBC) Intrinsic Value Is Potentially 87% Above Its Share Price

Mar 06
Embecta Corp.'s (NASDAQ:EMBC) Intrinsic Value Is Potentially 87% Above Its Share Price

Embecta: Weak Outlook But Mouth-Watering Valuation Skew Risk-Reward In Favour

Feb 28

New Initiatives Expected To Make Embecta More Profitable

Dec 04

Embecta (NASDAQ:EMBC) Is Due To Pay A Dividend Of $0.15

Nov 29
Embecta (NASDAQ:EMBC) Is Due To Pay A Dividend Of $0.15

At US$16.33, Is It Time To Put Embecta Corp. (NASDAQ:EMBC) On Your Watch List?

Nov 07
At US$16.33, Is It Time To Put Embecta Corp. (NASDAQ:EMBC) On Your Watch List?

It's A Story Of Risk Vs Reward With Embecta Corp. (NASDAQ:EMBC)

Sep 24
It's A Story Of Risk Vs Reward With Embecta Corp. (NASDAQ:EMBC)
author-image

Expanding Global Leadership In Insulin Devices Fuels Revenue Growth And Operational Efficiencies

Strengthening the base business in insulin injection devices suggests potential for stable, growing revenues as the global demographic needing these devices increases.

Embecta (NASDAQ:EMBC) Will Pay A Dividend Of $0.15

Aug 16
Embecta (NASDAQ:EMBC) Will Pay A Dividend Of $0.15

Embecta Corp. Just Beat EPS By 79%: Here's What Analysts Think Will Happen Next

Aug 14
Embecta Corp. Just Beat EPS By 79%: Here's What Analysts Think Will Happen Next

When Should You Buy Embecta Corp. (NASDAQ:EMBC)?

Jul 13
When Should You Buy Embecta Corp. (NASDAQ:EMBC)?

Earnings Beat: Embecta Corp. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

May 12
Earnings Beat: Embecta Corp. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Embecta's (NASDAQ:EMBC) Dividend Will Be $0.15

Feb 21
Embecta's (NASDAQ:EMBC) Dividend Will Be $0.15

Embecta Corp.'s (NASDAQ:EMBC) Prospects Need A Boost To Lift Shares

Jul 16
Embecta Corp.'s (NASDAQ:EMBC) Prospects Need A Boost To Lift Shares

Embecta Corp. (NASDAQ:EMBC) Shares Could Be 37% Below Their Intrinsic Value Estimate

Mar 30
Embecta Corp. (NASDAQ:EMBC) Shares Could Be 37% Below Their Intrinsic Value Estimate

Embecta Corp. Just Recorded A 22% EPS Beat: Here's What Analysts Are Forecasting Next

Feb 17
Embecta Corp. Just Recorded A 22% EPS Beat: Here's What Analysts Are Forecasting Next

Shareholder Returns

EMBCUS Medical EquipmentUS Market
7D1.3%-0.4%0.3%
1Y-20.1%7.8%10.9%

Return vs Industry: EMBC underperformed the US Medical Equipment industry which returned 7.3% over the past year.

Return vs Market: EMBC underperformed the US Market which returned 9.9% over the past year.

Price Volatility

Is EMBC's price volatile compared to industry and market?
EMBC volatility
EMBC Average Weekly Movement8.9%
Medical Equipment Industry Average Movement8.7%
Market Average Movement7.7%
10% most volatile stocks in US Market17.2%
10% least volatile stocks in US Market4.0%

Stable Share Price: EMBC has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: EMBC's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19242,100Dev Kurdikarwww.embecta.com

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes in the United States and internationally. The company’s products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient’s diabetes. It primarily sells its products to wholesalers and distributors.

Embecta Corp. Fundamentals Summary

How do Embecta's earnings and revenue compare to its market cap?
EMBC fundamental statistics
Market capUS$558.71m
Earnings (TTM)US$52.80m
Revenue (TTM)US$1.08b
11.1x
P/E Ratio
0.5x
P/S Ratio

Is EMBC overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
EMBC income statement (TTM)
RevenueUS$1.08b
Cost of RevenueUS$388.00m
Gross ProfitUS$691.50m
Other ExpensesUS$638.70m
EarningsUS$52.80m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)0.90
Gross Margin64.06%
Net Profit Margin4.89%
Debt/Equity Ratio-206.3%

How did EMBC perform over the long term?

See historical performance and comparison

Dividends

6.0%
Current Dividend Yield
66%
Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/06/16 16:02
End of Day Share Price 2025/06/16 00:00
Earnings2025/03/31
Annual Earnings2024/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Embecta Corp. is covered by 10 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Travis SteedBofA Global Research
Travis SteedBofA Global Research
Michael GormanBTIG